Tari, Akira, Kitadai, Yasuhiko, Mouri, Ritsuo, Takigawa, Hidehiko, Asaoku, Hideki, Mihara, Keiichiro, Takata, Katsuyoshi, Fujihara, Megumu, Yoshino, Tadashi, Koga, Tadashi, Fujimori, Shunji, Tanaka, Shinji, Chayama, Kazuaki
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 33(8) 1461-1468 2018年8月 査読有り
Background and AimFew reports have demonstrated the effectiveness of treatments for intestinal follicular lymphoma (FL) because of the limited number of patients who undergo comprehensive small intestinal examinations. This study compared the efficacy of rituximab-combined chemotherapy in patients with asymptomatic and low tumor burden (LTB) intestinal FL, according to the criteria of the Groupe d'Etude des Lymphomes Folliculaires, with that of a watch and wait (W&W) approach. MethodsThe endoscopic examination for entire gastrointestinal tracts was performed in 29 Japanese patients with intestinal FL. These patients had CD21-positive follicular dendritic cells arranged in a duodenal pattern. In a prospective, two-center, open-label trial, this study evaluated the efficacy of rituximab-combined chemotherapy ([cyclophosphamide, doxorubicin, vincristine, and prednisone] or [cyclophosphamide, vincristine, and prednisone]) and prolonged treatment with rituximab (R-Chemo+prolongedR) in 14 patients and compared their outcomes with those of 15 patients managed with a W&W approach. ResultsFour patients managed with the W&W plan showed worsening macroscopic findings, lesion area enlargement,